Kusum Healthcare Private Limited — Secnidazole Exporter Profile

Geopolitical & Trade Policy Impact on Kusum Healthcare Private Limited's Secnidazole Exports

The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Kusum Healthcare. Escalating tensions in the Middle East, particularly the Israel-Iran conflict, have disrupted key shipping routes such as the Red Sea and the Strait of Hormuz. These disruptions have led to increased freight charges, with surcharges ranging from $4,000 to $8,000 per shipment, posing a potential loss of ₹2,500 to ₹5,000 crore for the Indian pharmaceutical industry. (businesstoday.in)

Conversely, the U.S. pharmaceutical import policies are undergoing significant changes. The Trump administration's imposition of broad tariffs on imports from over 60 countries, including India, with rates reaching up to 39%, has introduced uncertainties. While these tariffs aim to spur domestic investment, they also risk disrupting global trade and increasing consumer prices. (apnews.com) For Kusum Healthcare, this necessitates a strategic reassessment of its export strategies to the U.S. market.

In the European Union, the implementation of the Falsified Medicines Directive (FMD) requires stringent compliance measures. Indian exporters must adapt to these regulatory changes to maintain market access. Additionally, the India–EFTA Trade and Economic Partnership Agreement, effective from October 2025, aims to eliminate or reduce tariffs on goods traded between India and EFTA countries, potentially opening new avenues for Kusum Healthcare in European markets. (en.wikipedia.org)